Rani Therapeutics Holdings (RANI) executive compensation, 2026 proxy

Talat Imran, Chief Executive Officer, was paid $1.1M in 2025, down 65% from $3M the year before.

Filed
April 16, 2026
Annual meeting
May 28, 2026
Pay year
2025
Named executives
3
CEO total pay
$1.1M-65% vs prior year
CEO Target Bonus
75%Percentage of annual base salary
CEO Reinstated Salary
$625,100Effective October 20, 2025
CFO Retention Payment
$139,000Cash retention payment in 2025
CBO Retention Payment
$130,000Cash retention payment in 2025

How Imran was paid

$1.1M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary19%Option awards48%Non-equity incentive33%

Named executive officers

ExecutiveTotal
Talat ImranChief Executive Officer$1,052,101
Svai SanfordChief Financial Officer$946,404
Kate McKinleyChief Business Officer$943,937

What changed and why

  • $1.1MTalat Imran total compensation decreased to $1,052,101 in 2025 following a higher prior year total of $3,042,245.
  • $198KTalat Imran received a salary of $198,325 reflecting temporary reductions and a subsequent reinstatement to $625,100.
  • $502KOption awards for Talat Imran were valued at $502,176 down from $2,936,227 in the prior year.
  • 75%Named Executive Officers earned non-equity incentive plan compensation based on a 75% achievement level of corporate goals.
  • $139KSvai Sanford and Kate McKinley received cash retention payments of $139,000 and $130,000 respectively under a retention program.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.